Capricor Therapeutics Inc [CAPR] stock prices are down -0.15% to $6.69 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CAPR shares have lost -10.56% over the last week, with a monthly amount glided 7.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on June 30, 2025, when Alliance Global Partners initiated its Buy rating and assigned the stock a price target of $20. Previously, B. Riley Securities started tracking the stock with Buy rating on June 26, 2025, and set its price target to $21. On May 20, 2025, Roth Capital initiated with a Buy rating and assigned a price target of $31 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $35 on October 21, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $14 as its price target on May 17, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on January 05, 2024, and assigned it a price target of $8. In a note dated October 26, 2022, Ladenburg Thalmann initiated a Buy rating and provided a target price of $15 on this stock.
The stock price of Capricor Therapeutics Inc [CAPR] has been fluctuating between $5.68 and $23.40 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $6.69 at the most recent close of the market. An investor can expect a potential return of 228.85% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
The Capricor Therapeutics Inc [NASDAQ:CAPR] reported sales of 13.39M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -5.48%, Pretax Profit Margin comes in at -5.22%, and Net Profit Margin reading is -5.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -0.63 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Capricor Therapeutics Inc [NASDAQ:CAPR]’s Current Ratio is 4.37. Further, the Quick Ratio stands at 4.37, while the Cash Ratio is 0.82. Considering the valuation of this stock, the price to sales ratio is 22.84, the price to book ratio is 2.91.
